FIELD: pharmacology.
SUBSTANCE: this composition comprises an anti-MSRV/HERV-W Env ligand and at least one nitric oxide inhibiting drug, the said ligand comprising each of the complementarity determining regions (CDRs) specified in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, and the said NO inhibitor drug is selected from the group consisting of NG-Nitro-L-arginine methyl ester (L-NAME), S-methyl isothiourea (SMT), fumaric acid and dimethyl fumarate (DMF).
EFFECT: presented inventions can be used to treat remyelination blockade in diseases associated with the expression of the HERV-W envelope protein.
6 cl, 31 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THE USE OF TRIS-(2-HYDROXYETHYL)AMMONIUM SALT OF 1-BENZYLINDOLYL-3-THIOACETIC ACID AS AN INHIBITOR OF THE ACTIVITY OF HUMAN ENDOGENOUS RETROVIRUS HERV-E λ 4-1 ENV | 2022 |
|
RU2801797C1 |
| ANTIRETROVIRAL DRUG AIMED AT HUMAN ENDOGENOUS RETROVIRUS | 2015 |
|
RU2689326C1 |
| COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 | 2017 |
|
RU2733886C2 |
| AGENTS AND METHODS BASED ON USING FIBRONECTIN OF DOMAIN EDA | 2006 |
|
RU2430738C2 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
| ANIMAL MODEL EXPRESSING LUCIFERASE UNDER CONTROL OF THE MYELIN BASIC PROTEIN PROMOTER (MBP-LUCI) AND USE OF THE MODEL FOR BIOLUMINESCENCE IN VIVO IMAGING | 2010 |
|
RU2601128C2 |
| METHODS AND COMPOSITIONS FOR IMMUNOMODULATION | 1997 |
|
RU2192281C2 |
| RECOMBINANT VACCINE AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 2006 |
|
RU2317107C2 |
| METHOD OF USE IN THERAPY | 2010 |
|
RU2579659C2 |
| METHOD OF PROVIDING REQUIRED LEVELS OF GLIAL GROWTH FACTOR 2 IN PLASMA | 2009 |
|
RU2530650C2 |
